Japan Tissue Engineering Co., Ltd. Logo

Japan Tissue Engineering Co., Ltd.

Pioneers regenerative medicine with tissue products, CDMO services, and research models.

7774 | T

Overview

Corporate Details

ISIN(s):
JP3389610001
LEI:
Country:
Japan
Address:
蒲郡市三谷北通6丁目209番地の1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Japan Tissue Engineering Co., Ltd. (J-TEC) is a pioneering biotechnology company focused on the commercialization of regenerative medicine. The company operates through three primary segments: the Regenerative Medicine Business, which develops, manufactures, and sells tissue-engineered medical products such as autologous cultured cartilage; the Custom Development & Manufacturing (CDMO) Business, offering contract services for cell and gene therapy developers; and the LabCyte Business, providing cultured human tissue models for research and safety testing. A member of the Teijin Group, J-TEC was the first company to commercialize regenerative medicine in Japan and aims to establish it as a standard of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:39
Registration Form
確認書
Japanese 8.3 KB
2025-11-13 07:37
Interim / Quarterly Report
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 190.7 KB
2025-06-19 10:05
AGM Information
臨時報告書
Japanese 27.0 KB
2025-06-19 07:20
Governance Information
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-19 07:18
Registration Form
確認書
Japanese 8.3 KB
2025-06-19 07:16
Annual Report
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 920.6 KB
2024-11-13 06:09
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-11-13 06:07
Interim / Quarterly Report
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 188.4 KB
2024-06-19 07:50
AGM Information
臨時報告書
Japanese 22.1 KB
2024-06-19 07:48
Governance Information
内部統制報告書-第26期(2023/04/01-2024/03/31)
Japanese 21.5 KB
2024-06-19 07:46
Registration Form
確認書
Japanese 8.3 KB
2024-06-19 07:45
Annual Report
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 907.6 KB
2024-02-13 06:39
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-02-13 06:38
Quarterly Report
四半期報告書-第26期第3四半期(2023/10/01-2023/12/31)
Japanese 169.5 KB
2023-11-14 07:22
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all Japan Tissue Engineering Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Japan Tissue Engineering Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Japan Tissue Engineering Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.